[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554778":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":21,"centralContacts":30,"locations":36,"responsibleParty":76,"collaborators":21,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":21,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":21,"overallStatus":38,"whyStopped":21,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Aalborg University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Lebrikizumab","EXPERIMENTAL","The initial doses will be subcutaneous Lebrikizumab 500 mg (two 250 mg injections) at both week 0 (baseline) and week 2, followed by 250 mg administered subcutaneously at week 4.",[13,14,15],"Other: Histamine","Other: Cowhage","Other: bovine adrenal medulla (BAM8-22)",[17,22,26],{"type":6,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"Histamine","A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.",[9],null,{"type":6,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Cowhage","Approximately 30-35 cowhage spicules will be manually inserted into the subject's skin.",[9],{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":21},"bovine adrenal medulla (BAM8-22)","A small drop of BAM8-22 solution will be applied to a previously determined area on the volar forearm followed by a prick through the drop.",[9],[31],{"name":32,"role":33,"phone":34,"phoneExt":21,"email":35},"Silvia Lo Vecchio","CONTACT","21397785","slv@hst.aau.dk",[37,61,67],{"facility":5,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Gistrup","Aalborg","9260","Denmark","DK",{"type":45,"coordinates":46},"Point",[47,48],9.99085,56.9943,{"lat":48,"lon":47},[51,53,57,59],{"name":52,"role":33,"phone":34,"phoneExt":21,"email":35},"Silvia Lo Vecchio, PhD",{"name":54,"role":33,"phone":55,"phoneExt":21,"email":56},"Botilla Markussen","20567502","bam@hst.aau.dk",{"name":52,"role":58,"phone":21,"phoneExt":21,"email":21},"PRINCIPAL_INVESTIGATOR",{"name":54,"role":60,"phone":21,"phoneExt":21,"email":21},"SUB_INVESTIGATOR",{"facility":62,"status":63,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":64,"geoPoint":66,"contacts":21},"CNAP","ACTIVE_NOT_RECRUITING",{"type":45,"coordinates":65},[47,48],{"lat":48,"lon":47},{"facility":5,"status":68,"city":40,"state":42,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"NOT_YET_RECRUITING",{"type":45,"coordinates":70},[71,72],9.9187,57.048,{"lat":72,"lon":71},[75],{"name":32,"role":33,"phone":21,"phoneExt":21,"email":21},{"type":58,"investigatorFullName":32,"investigatorTitle":77,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"Professor","100554778","role-of-interleukin-13-pathways-on-pain-and-itch-sensitivity-100554778",false,"NCT06503510","Role of Interleukin-13 Pathways on Pain and Itch Sensitivity","The Role of the Interleukin-13 Pathways on Pain and Itch Sensitivity in Patients With Atopic Dermatitis and Healthy Volunteers","IL-13","Inclusion Criteria:\n\n* Healthy men and women\n* 18-60 years\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Drug addiction defined as any use of cannabis, opioids, or other drugs\n* Previous or current history of neurological, dermatological (e.g., AD, psoriasis, etc.), immunological, musculoskeletal, cardiac disorder, or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.)\n* Moles, wounds, scars, or tattoos in the area to be treated or tested\n* Current use of medications that may affect the trial such as antihistamines and pain killers (use of antihistamines should be discontinued 72 hours before the experiment and all topical agents and emollients should be discontinued 24 hours before the experiment).\n* Use of systemic and topical corticosteroids\n* Consumption of alcohol or painkillers 24 hours before the study days and between these\n* Acute or chronic pain\n* Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)\n* Lack of ability to cooperate",true,"ALL","18 Years","60 Years",{"count":91,"type":92},20,"ESTIMATED","INTERVENTIONAL",[95],"NA","Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the proteins interleukins are involved in inflammation and itch in atopic dermatitis. The medicinal product called Lebrikizumab, used for treatment of AD, has shown to block the interleukin called IL-13. The purpose of this experiment is to evaluate the role of IL-13 in itch in both healthy subjects and people with atopic dermatitis.",[98],"Itch","2025-05-30",{"date":101,"type":102},"2025-06-04","ACTUAL",{"date":104,"type":102},"2025-01-06",{"date":106,"type":92},"2026-12-31",{"name":5,"class":6},3]